Marco Torella

Prof. Dr. Marco Torella

Department of Woman, Child and General and Specialized Surgery, Luigi Vanvitelli University of Campania, Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in European Urology
Verified
Journal Article
Closed access
Maurizio SeratiMaurizio Serati
Maurizio Serati
GBGiorgio Bogani
Giorgio Bogani
PSPaola Sorice
Paola Sorice
ABAndrea Braga
Andrea Braga
MTMarco Torella
Marco Torella
FGFabio Ghezzi
Fabio Ghezzi

1 June 2011 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
SSStefano Salvatore
Stefano Salvatore
SSsilvia salvatore
silvia salvatore
ECElena Cattoni
Elena Cattoni
GSGabriele Siesto
Gabriele Siesto
Maurizio SeratiMaurizio Serati
Maurizio Serati
MTMarco Torella
Marco Torella

1 March 2009 in Bone
Verified
Journal Article
Closed access
FRF. Rossi
F. Rossi
Dario SiniscalcoDario Siniscalco
Dario Siniscalco
Livio LuongoLivio Luongo
Livio Luongo
LPL. De Petrocellis
L. De Petrocellis
GBG. Bellini
G. Bellini
SMS. Maione
S. Maione

1 May 2012 in European Urology
Verified
Journal Article
Closed access
Maurizio SeratiMaurizio Serati
Maurizio Serati
FGFabio Ghezzi
Fabio Ghezzi
ECElena Cattoni
Elena Cattoni
ABAndrea Braga
Andrea Braga
GSGabriele Siesto
Gabriele Siesto
SSStefano Salvatore
Stefano Salvatore

12 September 2014 in Haematologica
Verified
Journal Article
Closed access
PDF file
FRF. Rossi
F. Rossi
SPSilverio Perrotta
Silverio Perrotta
GBG. Bellini
G. Bellini
Livio LuongoLivio Luongo
Livio Luongo
CTC. Tortora
C. Tortora
SMS. Maione
S. Maione
The pathogenesis of bone resorption in β-thalassemia major is multifactorial and our understanding of the underlying molecular and cellular mechanisms remains incomplete. Considering the emerging importance of the endocannabinoid/endovanilloid system in bone metabolism, it may be instructive to examine a potential role for this system in the development of osteoporosis in patients with β-thalassemia major and its relationship with iron overload and iron chelation therapy. This study demonstrates that, in thalassemic-derived osteoclasts, tartrate-resistant acid phosphatase expression inversely correlates with femoral and lumbar bone mineral density, and directly correlates with ferritin levels and liver iron concentration. The vanilloid agonist resiniferatoxin dramatically reduces cathepsin K levels and osteoclast numbers in vitro, without affecting tartrate-resistant acid phosphatase expression. The iron chelators deferoxamine, deferiprone and deferasirox decrease both tartrate-resistant acid phosphatase and cathepsin K expression, as well as osteoclast activity. Taken together, these data show that transient receptor potential vanilloid type 1 activation/desensitization influences tartrate-resistant acid phosphatase expression and activity, and this effect is dependent on iron, suggesting a pivotal role for iron overload in the dysregulation of bone metabolism in patients with thalassemia major. Our applied pharmacology provides evidence for the potential of iron chelators to abrogate these effects by reducing osteoclast activity. Whether iron chelation therapy is capable of restoring bone health in humans requires further study, but the potential to provide dual benefits for patients with β-thalassemia major –preventing iron-overload and alleviating associated osteoporotic changes – is exciting.

1 September 2011 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
LCLuigi Cobellis
Luigi Cobellis
MCMaria Antonietta Castaldi
Maria Antonietta Castaldi
VGValentino Giordano
Valentino Giordano
ETElisabetta Trabucco
Elisabetta Trabucco
PFPasquale De Franciscis
Pasquale De Franciscis
NCNicola Colacurci
Nicola Colacurci